View Older Stories View More Recent Stories

Feb 28, 2024 04:05PM Sarepta Therapeutics Announces Fourth Quarter and Full-Year 2023 Financial Results and Recent Corporate Developments
Feb 21, 2024 08:30AM Sarepta Therapeutics to Announce Fourth Quarter and Full-Year 2023 Financial Results
Feb 16, 2024 07:00AM Sarepta Therapeutics (SRPT) Announces FDA Acceptance of an Efficacy Supplement to Expand the ELEVIDYS Indication
Feb 16, 2024 07:00AM Sarepta Therapeutics Announces U.S. FDA Acceptance of an Efficacy Supplement to Expand the ELEVIDYS Indication
Jan 31, 2024 06:29PM Sarepta Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
Jan 29, 2024 07:01AM Sarepta Therapeutics (SRPT) Announces Positive Data from Part B of MOMENTUM Study
Jan 29, 2024 07:00AM Sarepta Therapeutics Announces Positive Data from Part B of MOMENTUM, a Phase 2 Study of SRP-5051 in Patients with Duchenne Muscular Dystrophy Amenable to Skipping Exon 51
Jan 16, 2024 09:02AM Sarepta Therapeutics Initiates Screening in EMERGENE, a Phase 3 Clinical Study of SRP-9003 for the Treatment of Limb-Girdle Muscular Dystrophy Type 2E/R4
Jan 8, 2024 11:55AM Sarepta Therapeutics (SRPT) Reports Preliminary Fourth Quarter and Full-Year 2023 Net Product Revenue
Jan 8, 2024 11:55AM Sarepta Therapeutics Reports Preliminary* Fourth Quarter and Full-Year 2023 Net Product Revenue
Jan 2, 2024 08:30AM Sarepta Therapeutics to Present at the 42nd Annual J.P. Morgan Healthcare Conference
Dec 29, 2023 06:27PM Sarepta Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
Dec 22, 2023 08:01AM Sarepta Therapeutics (SRPT) Submits Efficacy Supplement to Expand the ELEVIDYS Label to include DMD Patients without Restriction to Age or Ambulatory Status
Dec 22, 2023 08:00AM Sarepta Therapeutics Submits Efficacy Supplement to Expand the ELEVIDYS Label to include Duchenne Muscular Dystrophy Patients without Restriction to Age or Ambulatory Status
Nov 30, 2023 06:34PM Sarepta Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
Nov 15, 2023 08:10PM SRPT LOSS ALERT: ROSEN, A LEADING INVESTOR RIGHTS LAW FIRM, Encourages Sarepta Therapeutics, Inc. Investors to Inquire About Securities Class Action Investigation – SRPT
Nov 2, 2023 08:30AM Sarepta Therapeutics to Present at the UBS Biopharma Conference
Nov 1, 2023 04:05PM Sarepta Therapeutics Announces Third Quarter 2023 Financial Results and Recent Corporate Developments
Oct 31, 2023 07:02PM Sarepta Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
Oct 30, 2023 04:20PM Sarepta Therapeutics' (SRPT) EMBARK Study Did Not Meet Primary Endpoint but Data Shows Robust, Statistically Significant Results
Oct 30, 2023 04:01PM Sarepta Therapeutics Announces Topline Results from EMBARK, a Global Pivotal Study of ELEVIDYS Gene Therapy for Duchenne Muscular Dystrophy
Oct 25, 2023 08:30AM Sarepta Therapeutics to Announce Third Quarter 2023 Financial Results
Sep 29, 2023 06:30PM Sarepta Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
Sep 7, 2023 09:00AM Sarepta Therapeutics Announces Recipients of the 6th Annual Route 79, The Duchenne Scholarship Program, for the 2023-2024 Academic Year
Sep 5, 2023 08:30AM Sarepta Therapeutics to Present at the Morgan Stanley 21st Annual Global Healthcare Conference
Aug 31, 2023 06:15PM Sarepta Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
Aug 30, 2023 08:42AM Quest Diagnostics (DGX) granted Breakthrough Device Designation from FDA for AAV test
Aug 30, 2023 08:40AM Quest Diagnostics Granted FDA Breakthrough Designation for its Adeno-associated virus (AAV) Test
Aug 2, 2023 04:05PM Sarepta Therapeutics Announces Second Quarter 2023 Financial Results and Recent Corporate Developments
Jul 31, 2023 06:08PM Sarepta Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
Jul 26, 2023 08:30AM Sarepta Therapeutics to Announce Second Quarter 2023 Financial Results
Jul 5, 2023 08:30AM Sarepta Therapeutics (SRPT) Announces Sale of Priority Review Voucher for $102 million
Jul 5, 2023 08:30AM Sarepta Therapeutics Announces Sale of Priority Review Voucher for $102 million
Jul 3, 2023 08:30AM Sarepta Therapeutics to Present at Cowen's 2nd Annual RNA Therapeutics Summit
Jun 30, 2023 06:20PM Sarepta Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
Jun 22, 2023 02:02PM Sarepta Therapeutics (SRPT) Announces FDA Approval of ELEVIDYS, the First Gene Therapy to Treat Duchenne Muscular Dystrophy
Jun 22, 2023 02:02PM Sarepta Therapeutics Announces FDA Approval of ELEVIDYS, the First Gene Therapy to Treat Duchenne Muscular Dystrophy
May 31, 2023 06:16PM Sarepta Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
May 24, 2023 08:09AM Sarepta Therapeutics (SRPT) reports FDA requires additional time to complete review of SRP-9001
May 24, 2023 08:00AM Sarepta Therapeutics Announces Update on Regulatory Review of SRP-9001
May 15, 2023 05:37AM Sarepta Therapeutics (SRPT) Reports Positive FDA AdCom Vote for SRP-9001
May 12, 2023 07:02PM Sarepta Therapeutics Announces Positive Vote from U.S. FDA Advisory Committee Meeting for SRP-9001 Gene Therapy to Treat Duchenne Muscular Dystrophy
May 2, 2023 04:05PM Sarepta Therapeutics Announces First Quarter 2023 Financial Results and Recent Corporate Developments
Apr 28, 2023 06:15PM Sarepta Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
Apr 25, 2023 08:30AM Sarepta Therapeutics to Announce First Quarter 2023 Financial Results
Apr 10, 2023 09:37AM Sarepta Therapeutics Announces that the Date of the Advisory Committee Meeting for SRP-9001 will be May 12, 2023
Apr 9, 2023 11:47AM ROSEN, TRUSTED INVESTOR COUNSEL, Encourages Sarepta Therapeutics, Inc. Investors to Inquire About Securities Class Action Investigation – SRPT
Mar 31, 2023 06:25PM Sarepta Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
Mar 16, 2023 05:44PM Sarepta Therapeutics (SRPT) announced AdCom to be held for SRP-9001
Mar 16, 2023 04:05PM Sarepta Therapeutics Announces Advisory Committee Meeting will be Held for SRP-9001
View More Recent Stories View Older Stories